What the research actually shows
A place to read carefully alongside readers who are genuinely interested in these compounds. We're not here to debunk anything — we're here to take an honest look at what the published research shows, where the picture is genuinely promising, and where it's still being built.
Why we wrote this section
Peptide research moves fast. Marketing claims travel faster. The space between "this is exciting" and "this has been clinically demonstrated in humans" is where most readers lose the thread — not because they're being credulous, but because the evidence-grading framework is genuinely hard to apply across compounds with very different research traditions.
The articles below are an attempt to read that space carefully. Some compounds emerge looking better than the dismissive coverage suggests; others emerge looking less established than the enthusiastic coverage suggests. The point is calibration — and respect for readers who are doing their own work.
How to read the verdicts
Established — multiple Phase 3 trials and approved indications. Promising — credible biology with positive early- or mid-stage human evidence. Mixed — real signals plus methodological or translational concerns. Calibration — recalibrating expectations against the underlying data. Field overview — broader research-tradition or framework reads. Want more on the framework? Read our methodology.
Specific compounds & claims · 8 reads
Deep-dives on the most-discussed individual peptides and the specific claims that surround them.
The BPC-157 tendon question
What does the BPC-157 literature actually look like? The animal-model record is broader than skeptics admit and the human-trial record is thinner than enthusiasts admit. Let's walk through both carefully and see where the picture lands.
Read articleMOTS-c and the mitokine revolution
A peptide encoded inside the mitochondrial genome that signals to the rest of the cell — and declines with age. The basic biology is one of the more exciting stories in the longevity peptide space. Where does the research actually stand, and what are the right expectations?
Read articleRetatrutide before Phase 3: what the trials show so far
The Phase 2 weight-loss numbers were remarkable. The Phase 3 program is still running. What did the trials actually show, what hasn't been answered yet, and what should readers be watching for in the next 18 months?
Read articleThe exercise-mimetic question — SLU-PP-332, AICAR, and what we've learned
SLU-PP-332's mouse data is striking. So was AICAR's, fifteen years ago. So was GW501516's, before the cancer signals. What does the history of exercise-mimetic candidates tell us about how to read the latest one?
Read articleTirzepatide vs Semaglutide: a careful head-to-head reading
The most-asked comparison in modern obesity medicine. The SURMOUNT vs STEP data, the dual-agonist mechanism, and why the head-to-head SURPASS-2 trial reframed the conversation. What the trial reading actually supports — and where the comparison gets more complicated.
Read articleCJC-1295 + Ipamorelin: the most-stacked combination examined
The classic GH-secretagogue stack that defines the modern peptide-research community. Mechanistically clean, pharmacokinetically reasonable, and supported by Phase 1 data on GH/IGF-1 elevation. The interesting question is what those biochemical changes actually translate into — and where the evidence gap lies.
Read articleEpitalon and the Khavinson telomere story
The most internationally-recognized peptide of the Khavinson framework — a pineal-derived tetrapeptide associated with telomerase activity in originating-group studies. The framework is real, the research lineage is decades-deep, and the evidence base is concentrated in one tradition. Reading the picture honestly.
Read articleDIHEXA: the '100,000× BDNF' claim, examined
An angiotensin IV-derived hexapeptide whose 2012 cell-culture paper produced one of the most-quoted potency claims in modern nootropic discussion. The original finding is real; what it actually means clinically is a much narrower question. Reading the gap between cell-culture potency and clinical translation.
Read articleCategories & traditions · 8 reads
The broader research traditions and product categories that shape how peptides are discussed and used.
The Russian peptide research tradition
Semax, Selank, Cerebrolysin, the Khavinson short peptides, Epitalon — five compounds and a research tradition that produced them. What can we take from the Russian-language literature, what should be calibrated, and what's been overlooked in Western coverage?
Read articleAnti-aging skincare peptides — small effects, real ones
Argireline, Matrixyl, copper peptides — the cosmetic peptide marketplace runs on big claims, but the research underneath is real and the modest effects in trials are worth knowing about. A balanced read on what topical peptide therapy actually does.
Read articleThe ghrelin axis — real biology, modest expectations
Ipamorelin, hexarelin, MK-677, anamorelin — these compounds reliably elevate growth hormone and IGF-1. The question is what those biochemical changes mean for body composition, recovery, and longevity in healthy adults. The honest answer is interesting.
Read articleCerebrolysin around the world
A peptide-amino-acid mixture used in 50+ countries for stroke, TBI, and dementia, with a clinical track record longer than most peptide therapeutics combined. Why is the evidence simultaneously substantial and difficult to evaluate?
Read articleThe myostatin inhibitor class: from Stamulumab to Bimagrumab
A 20-year arc through the development of pharmacologic myostatin-pathway inhibition — three discontinuations, several pivots, and the modern combination strategies that emerged from the lessons of each. How the field got from animal-model striking results to a drug class on the verge of changing obesity standard of care.
Read articleDual and triple agonists in obesity medicine
From semaglutide (GLP-1 mono) to tirzepatide (GIP/GLP-1 dual) to retatrutide (GIP/GLP-1/glucagon triple) — the engineering strategy that has produced progressively deeper weight loss with each generation. How the field got here, what each receptor arm contributes, and what the limits of receptor-stacking might be.
Read articleThe amylin pathway: from Pramlintide to CagriSema
Amylin has been the second-most-important obesity-pharmacology peptide hormone for nearly three decades — co-secreted with insulin, contributing to satiety and gastric-emptying biology distinct from GLP-1. The pharmacology arc from pramlintide (FDA-approved 2005) to cagrilintide and CagriSema is the modern combination story that's reshaping how we think about incretin therapy.
Read articleConotoxins, snail venom, and therapeutic peptides from nature
Ziconotide is one of the more underappreciated peptide therapeutics of modern medicine — a synthetic version of cone snail venom approved as an intrathecal non-opioid analgesic. The story sits at the intersection of natural-product chemistry, ion-channel pharmacology, and the surprising therapeutic potential of compounds whose original biological role was killing prey.
Read articleCross-cutting questions · 8 reads
Field-level questions that apply across compounds — regulatory landscape, translational lessons, and what the GLP-1 era taught us.
Are senolytics ready for prime time?
FOXO4-DRI, dasatinib + quercetin, fisetin, navitoclax — the senolytics field has produced fascinating preclinical biology and early-phase human studies. Where does the evidence currently stand, and what would have to be true for senolytic therapy to become a clinical reality?
Read articleWhat we've learned from the GLP-1 explosion
A retrospective on the most consequential pharmacology story of the past decade. The cardiovascular and renal outcomes data, the mental-health and addiction signals, the muscle-preservation question, the access dynamics — what the GLP-1 era is teaching the broader peptide field.
Read articleCompounded vs research-grade vs FDA-approved
What's actually different across the three tiers of peptide availability? How do regulatory pathways, quality oversight, and product identity vary? A practical framework for readers navigating a confusing marketplace.
Read articlePeptides where the controlled human evidence is still emerging
Compounds that are household names in performance, recovery, and longevity communities — and where the controlled human-trial evidence is still a development frontier. Worth understanding which peptides sit in this space and why.
Read articleCardiovascular outcomes trials and why they reshape pharmacology
SELECT, FLOW, LEADER, REWIND, SUSTAIN-6 — the cardiovascular outcomes trials that have transformed GLP-1 therapy from a glycemic-and-weight intervention into a cardiovascular-and-renal class. Why CVOTs reshape clinical practice in ways that surrogate-endpoint trials don't, and what the same logic implies for the next decade of peptide therapeutics.
Read articleTranslation gaps: when animal models don't predict human effects
Striking effects in mice or rats are common in peptide pharmacology; clinical translation to comparable effects in humans is much rarer. Why preclinical-to-clinical translation fails, what the patterns of failure look like, and how to read animal-model claims more accurately.
Read articleGLP-1 muscle preservation: real concern or manageable trade-off?
About 25-40% of GLP-1-driven weight loss is lean mass — a finding that has driven both legitimate concern and substantial overstatement. What the lean-mass numbers actually mean, where they sit relative to other weight-loss methods, and how the muscle-preservation pharmacology pipeline is responding.
Read articleThe grey market: identity, purity, and practical harm reduction
A substantial fraction of the peptides discussed online are sourced through research-peptide vendors operating in regulatory grey zones. The identity, purity, and source-quality questions are real and consequential. What the evidence shows about grey-market peptide quality, what's typical for those who source this way, and how harm-reduction principles apply.
Read articleFor deeper reading
Every Honest Read links to the underlying peptide pages and to relevant theoretical stacks. The GLP-1 Hub is the most-developed area of the site for evidence-grade material on metabolic peptides. The Research Library aggregates the underlying citations.